Senior Managing Director
Senior Managing Director
Francois Maisonrouge is a Senior Managing Director in Evercore Partners’ advisory business with 31 years of relevant experience.
At Evercore, among other transactions, Mr. Maisonrouge was involved in advising Medivation on its sale to Pfizer, AstraZeneca on the sale of its anti-infectives business to Pfizer, Shire on its acquisitions of Baxalta and Dyax, Shire on its defense across from Abbvie, AstraZeneca in its defense across from Pfizer, Sun Pharmaceutical Industries on its acquisition of Ranbaxy Laboratories, Bristol-Myers Squibb on its acquisition of Amylin and sale of half of its interest in Amylin to AstraZeneca, Fenwal on its sale to Fresenius, Terumo on its acquisition of CaridianBCT, Sanofi on its acquisition of Genzyme and of Merck’s 50% stake in Merial, TPG on its acquisition of IMS Health, and Wyeth on its combination with Pfizer.
Prior to joining Evercore, Mr. Maisonrouge was a Managing Director and Chairman of Life Sciences at Credit Suisse where he worked extensively in the fields of pharmaceuticals, specialty pharmaceuticals, biotechnology and medical technology.
Mr. Maisonrouge has an M.S. in Engineering from Ecole Centrale de Lyon and an M.B.A. from Harvard Business School. He is a member of the Board of Advisors of the Harvard Business School Health Care Initiative, and a Director of the Pasteur Foundation. In 2014, Mr. Maisonrouge was awarded the rank of Chevalier de la Légion d’Honneur.
Life Sciences Consortium
LSC Task Force Participation
Task Force Member(s): François Maisonrouge, Senior Managing Director
Evercore Partners LLC
Evercore is a premier independent investment banking advisory firm.
We founded Evercore in 1995, on the premise that clients would be best served by an investment banking firm free of the conflicts of interest inherent to large, multi-product financial institutions. We believed our model would attract the most talented senior finance professionals to our firm. We believed that by maintaining the highest standards of excellence we could create a firm unlike any other in terms of capabilities to advise on highly complex strategic transactions, dedication to our client and our experience and professionalism.
Today, we serve a prominent and diverse set of clients and investors, including leading multinational corporations, large institutional investors and financial sponsors, and high net worth individuals.
Our global expansion continues in order to ensure the worldview and international knowledge base that is now critical to all investors. Today, our offices in North America, Europe, Mexico, Brazil, Hong Kong and Singapore are complemented by strategic alliances with leading firms in China, Japan, India, Korea, Australia and Argentina.
We always strive to enhance our capabilities and expand our global reach thereby providing the highest caliber of various services to our clients.